OCS
Strong SellSinkerOculis Holding AG · Healthcare · Switzerland · $678M · Avg Vol: $2M/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT OCULIS HOLDING AG
Read
Oculis Holding AG is a clinical-stage biopharmaceutical company dedicated to developing innovative topical treatments for serious ophthalmic diseases. The company's competitive edge lies in its proprietary OCS-01 drug candidate and advanced formulation technologies, aiming to deliver therapeutic benefits directly to the eye without the need for injections or implants.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 1.1M | 5.0M | — |
| EPS | -13.77 | -3.61 | -2.58 | -2.30 | — | -1.68 | -1.90 | -2.00 | — |
| Shares | 32.7M | 36.6M | 43.7M | 58.0M | +77.1% | 55.5M | — | — | — |
| Debt | 0.8M | 0.7M | 1.4M | 2.8M | 54.0% | 3.1M | — | — | — |
| Equity | -119.2M | 114.1M | 89.3M | 238.6M | 44.6% | — | — | — | — |
| Op CF | -30.5M | -67.0M | -59.5M | -80.7M | — | -79.6M | — | — | — |
| Inv CF | -4.3M | -64.5M | -19.6M | -74.1M | — | — | — | — | — |
| Fin CF | 2.1M | 157.7M | 65.7M | 227.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OCS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OCS | Oculis Holding AG(you) | $678M | 6 | Strong Sell |
| MLTX | MoonLake Immunotherapeutics | $1.3B | 8 | Strong Sell |
| ACIU | AC Immune SA | $299M | 13 | Strong Sell |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 20 | Sell |
| IDIA.SW | Idorsia Ltd | $1.7B | 22 | Sell |
| MOLN | Molecular Partners AG | $172M | 19 | Strong Sell |
| PHVS | Pharvaris N.V. | $2.5B | 21 | Sell |
| CRSP | CRISPR Therapeutics AG | $5.6B | 20 | Sell |
| BANB.SW | Bachem Holding AG | $7.1B | 53 | Hold |
| BSLN.SW | Basilea Pharmaceutica AG | $986M | 97 | Strong Buy |
Peer medians: ROE 11.1% · P/E 29.9x · Gross margin 60.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.